Gene's newly explained effect on height may change tumor disorder treatment

August 12, 2008

A mutation that causes a childhood tumor syndrome also impairs growth hormone secretion, researchers at Washington University School of Medicine in St. Louis have found.

The discovery provides new insights into an old mystery, revealing why patients with neurofibromatosis type 1 are frequently shorter than their peers. The surprising details have led scientists to consider modifying their search for treatments for the inherited disorder, which is caused by a mutation in the neurofibromin 1 (NF1) gene and is characterized by an increased risk of cancer.

"We've learned that the NF1 gene affects stature through a different pathway than the one we've previously focused on to understand cancers in patients with neurofibromatosis type 1," says Washington University neurologist David H. Gutmann, M.D., Ph.D., a Washington University neurologist who treats individuals with neurofibromatosis at St. Louis Children's Hospital. "Given that this second pathway has been linked to cancer in other contexts, we may need to consider the possibility that it is contributing to these tumors and alter our treatment goals accordingly."

The results appear online in the journal Human Molecular Genetics.

Neurofibromatosis 1 affects more than 100,000 people in the United States and is one of the most common tumor predisposition syndromes. The severity of the condition varies.

The NF1 protein, called neurofibromin, influences a number of different growth control pathways. Until now, much research focused on neurofibromin's effects on RAS protein activity, which is linked to cell growth, proliferation and cancer. Normally, NF1 deactivates RAS proteins. In its absence, scientists believe unchecked RAS can promote cancer development.

To learn more, Gutmann's lab created a line of mice in which stem cells in the brain do not make the NF1 protein. They found that these mice were significantly smaller than normal and failed to grow and gain weight after birth.

Balazs Hegedus, Ph.D., a postdoctoral researcher in Gutmann's laboratory, noticed that the pituitary glands, which produce growth hormone, also were unusually small in these mice. The amount of a second hormone that triggers growth hormone release was also greatly reduced.

"We wanted to know if we could blame this on RAS protein activity, so we generated new mice with normal levels of neurofibromin expression, but increased levels of RAS activation in brain stem cells," says Gutmann, the Donald O. Schnuck Family Professor of Neurology, and director of Washington University Neurofibromatosis Center. "However, those mice were normal."

NF1 also increases brain levels of cyclic AMP (cAMP), an important signaling molecule. Working with the same line of mice where stem cells in the brain do not make the NF1 protein, researchers fed pregnant mice and their newborns an agent that increased cAMP levels. The baby mice were closer to normal size, even though they still lacked neurofibromin in brain stem cells. Gutmann suspects the mice didn't completely return to normal because dietary supplementation of cAMP levels cannot match the natural ability of neurofibromin to control cAMP levels.

Gutmann is intrigued by the connection to cAMP. Research in other disorders has begun to build a number of associations between cAMP and tumor formation. Gutmann's laboratory and others have treatments in the works for neurofibromatosis 1 that restore the inhibitory effect neurofibromin normally has on RAS, but the new results may mean treatments are also needed to restore neurofibromin's effects on cAMP levels.

"What we've learned also may help us gain insight into other disease processes," Gutmann notes. "There are a number of other rare genetic abnormalities that cause short stature, and this same pathway may be involved."

To follow up, Gutmann plans additional studies to explore the role of the NF1 gene in the pituitary gland and the hypothalamus, a brain region that controls pituitary gland production of growth hormone.

Washington University School of Medicine

---

---

	Thriving With Neurofibromatosis by Kristi Hopkins (Author) 1 in 3000 people are born with Neurofibromatosis. It affects all of us in different ways. For some, Neurofibromatosis is as clear as the tumors on their face. For others, it hides beneath the surface, creating tumors that destroy hearing, vision, and more. Many of us are misdiagnosed, misunderstood, and often simply missed by a world of medicine that doesn't have a full grasp on all teh effects of NF. Stereotyped, ignored, or shunned by a world who thinks we either have the Elephant Man's disease, common migraines, or a few too many moles and birthmarks. In a society that values beauty so highly, NF'ers often choose to hide from others, and end up hiding from themselves. In 2007, Kristi chose to stop hiding, and start Thriving, as NF became a bigger part of my life than...
	Neurofibromatosis: A Handbook for Patients, Families and Health Care Professionals by Bruce R. Korf (Editor), Allen E. Rubenstein (Editor) Here is the state-of-the-art on recognizing, managing and living with neurofibromatosis (NF) for patients, families, and health care professionals. From new genetic and diagnostic advances, to associated cardiovascular and endocrine abnormalities, to the significant psychosocial impact of NF, the book is packed with clear, practical guidance for understanding and living with this disability.Special features:A complete diagnostic guide to help you recognize NF-related symptoms--with a timeline for when they might appear New treatment options for NF, including pain control Coverage of the newly discovered form of NF, schwannomatosis Personal perspectives from NF patients and their families Glossary that defines medical terminologyWith the great diagnostic and treatment...
	Neurofibromatosis: Causes, Tests and Treatment Options by Anthony S Michaels MA (Author), Jennifer Grange MD (Editor) Neurofibromatosis is a disease that disturbs the proper growth of the cells of your nervous system. It is genetic, which means that you may suffer from it because one or both of your parents had this disease. If you get affected with neurofibromatosis, you have an increased risk of being affected with other kinds of tumors related to nervous system, such as spinal cord tumors. Cancer is caused by neurofibromatosis tumors in very rare cases. So far, there is no definite cure for neurofibromatosis. However, researchers and clinicians have discovered new ways to treat patients with specific neurofibromatosis-related problems.
	Kirsty's Story: Living with Neurofibromatosis and Scoliosis by Kirsty Ashton (Author)
	The Man Who Murdered Himself: A Short Story Kyle Ameus Waterbey is afflicted with a hideous illness. He would do anything to be rid of it. Anything. Kyle suffers from neurofibromatosis, a crippling disease most famously associated with the Elephant Man.  When a shady medical practitioner offers Kyle a chance to cast off his deformed appearance forever, he accepts without a second thought.  But does Kyle truly understand what this new treatment will cost him? This story has won a Phobos Award and the Vera Hinckley Mayhew Award.  It is also included in the collection Dead Men Don't Cry: 11 Stories by Nancy Fulda. About 8 pages or 3,000 words.
	I'm Not Sick, Just A Bit Unwell by Kia Kaha Press Yvonne Foong was just sixteen when she was diagnosed with neurofibromatosis, a genetic illness with no cure. That discovery propelled her into the fight of her life, and she embarked on an odyssey to America to treat the tumours raging within her. Stark and revealing, this memoir peels back the curtains on her experience and reveals exactly what it means to endure the unendurable. It's an inspiring journey which captivated a nation, winning Yvonne Foong the title of Most Outstanding Youth at the 2005 Dream Malaysia Awards. Straddling borders and cultures, this is a story of friendship, faith and hope. A story you won’t soon forget. *** EXCERPT I was seated comfortably in the doctor’s office that day. The other...
	Living with Genetic Disorder: The Impact of Neurofibromatosis 1 by Joan Ablon (Author) A description of the social, educational, and economic impact of living with a neurological genetic disorder, neurofibromatosis 1. The many unpredictable and potentially stigmatizing possible symptoms of NF1, which range from physical disfigurement to severe learning disorders, may have serious consequences in every aspect of daily life. NF1 was for many years wrongly diagnosed as the Elephant Man's Disease.Ablon examines the psychosocial costs of this misdiagnosis and the ways in which stage, screen, and television parlayed The Elephant Man into the personification of the grimmist extreme of ugliness. This portrayal engendered fear and anxiety for affected persons and their families and also had an impact on the scientific and medical communities. Ablon analyzes the factors that affect...
	Neurofibromatosis: Trusting God in the midst of NF by Renee B Wilson (Author)
	Advances in Neurofibromatosis Research (Neurology-Laboratory and Clinical Research Developments: Genetics-Research and Issues) by Karin Soares Goncalves Cunha (Editor), Mauro Geller (Editor) This is a practical and objective book that provides an updated and comprehensive overview, offering insight into the research advances in neurofibromatosis. This book represents a reference source for researchers, healthcare professionals from various fields, as well as students, about different aspects of neurofibromatosis. In addition, this book useful guidance to researchers and health professionals seeking to contribute to longevity and improved quality of life for patients and their families.
	Neurofibromatosis: Phenotype, Natural History, and Pathogenesis (Johns Hopkins Series in Contemporary Medicine and Public Health) by Dr. J. M. Friedman MD PhD (Editor), Dr. David H. Gutmann MD-PhD (Editor), Dr. Mia MacCollin MD (Editor), Dr. Vincent M. Riccardi MD (Editor) Now in its third edition, Neurofibromatosis has been extensively rewritten by a group of leading neurofibromatosis (NF) researchers. It summarizes the current state of knowledge and details significant advances in the basic science and clinical care of patients with NF1 and NF2. Areas of particular emphasis include aspects of natural history, variability, pathology, molecular biology, and cellular biology that give a deeper understanding of the mechanisms responsible for these diseases. The book is a definitive, comprehensive review of the history, heterogeneity, pathogenesis, genetics, and management of NF1 and NF2.Praise for the second edition:"For anyone embarking on scientific and clinical research of neurofibromatosis, the Riccardi book, particularly in view of its exhaustive...